Sugi Predict

Sugi Predict / Compounds / SCHEMBL981027

SCHEMBL981027

SCHEMBL981027

O=[N+]([O-])c1cccc(S(=O)(=O)O)c1CC1CO1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 6/20 0.41
▸ MEN1 O00255 3/20 0.41
▸ PRMT5 O14744 1/20 0.40
▸ WDR77 Q9BQA1 1/20 0.40
▸ CA1 P00915 1/20 0.39
▸ CA2 P00918 1/20 0.39
▸ MMP1 P03956 1/20 0.39
▸ MMP2 P08253 1/20 0.39
▸ MMP9 P14780 1/20 0.39
▸ MMP8 P22894 1/20 0.39
▸ MMP13 P45452 1/20 0.39
▸ ALDH1A1 P00352 3/20 0.38
▸ MCOLN3 Q8TDD5 1/20 0.38
▸ POLB P06746 2/20 0.37
▸ ATM Q13315 1/20 0.37
▸ TDP1 Q9NUW8 1/20 0.37
▸ F2 P00734 1/20 0.37
▸ PRSS1 P07477 1/20 0.37
▸ PRSS2 P07478 1/20 0.37
▸ PRSS3 P35030 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL336604 1.00 KMT2A (0.41) KMT2AMEN1PRMT5WDR77CA1
SCHEMBL1694151 1.00 KMT2A (0.41) KMT2AMEN1PRMT5WDR77CA1
SCHEMBL1787921 1.00 KMT2A (0.41) KMT2AMEN1PRMT5WDR77CA1
SCHEMBL1720326 1.00 KMT2A (0.41) KMT2AMEN1PRMT5WDR77CA1
SCHEMBL981024 1.00 KMT2A (0.41) KMT2AMEN1PRMT5WDR77CA1
SCHEMBL28290358 0.85 KMT2A (0.43) KMT2AMEN1ALDH1A1MCOLN3POLB
SCHEMBL28290356 0.85 KMT2A (0.43) KMT2AMEN1ALDH1A1MCOLN3POLB
SCHEMBL20502306 0.82 PRMT5 (0.44) KMT2AMEN1PRMT5WDR77ALDH1A1
SCHEMBL28853079 0.82 KMT2A (0.34) KMT2AMEN1PRMT5WDR77ALDH1A1
SCHEMBL28853081 0.82 KMT2A (0.34) KMT2AMEN1PRMT5WDR77ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 196 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119708491-A Polydisulfide polymer material containing hydroxy ester group and preparation method thereof 衢州化工新材料创新研究院 2025-03-28 — — CN claimed
CN-118126009-A Coumarin derivative, preparation method and application 成都纽瑞特医疗科技股份有限公司 2024-06-04 — — CN claimed
WO-2014140220-A1 PROCESS FOR THE PREPARATION OF (2,3-DIHYDRO-BENZO[B][1,4]DIOXIN-2-YL) METHANOL DERIVATIVES JANSSEN PHARMACEUTICA, N.V. (BE) 2014-09-18 — — WO claimed
US-20140275576-A1 PROCESS FOR THE PREPARATION OF (2,3-DIHYDRO-BENZO[B][1,4]DIOXIN-2-YL) METHANOL DERIVATIVES JANSSEN PHARMACEUTICA NV (BE) 2014-09-18 — — US claimed
US-7772334-B2 Crosslinker of reactive functional groups and nonionic metal coordinating structure-containing alkyl or aromatic compound BASF COATINGS GMBH (DE) 2010-08-10 — — US claimed
US-7759436-B2 Film-former of resin with nonionic metal coordinating structure and crosslinker-reactive group BASF COATINGS GMBH (DE) 2010-07-20 — — US claimed
WO-2008016199-A1 PROCESS FOR THE PREPARATION OF CHIRAL 2-HYDROXYMETHYL-1,4-BENZODIOXANE COMPOUND AHN-GOOK PHARMACEUTICAL CO., LTD. (KR) 2008-02-07 — — WO claimed
CN-119708491-A Polydisulfide polymer material containing hydroxy ester group and preparation method thereof 衢州化工新材料创新研究院 2025-03-28 — — CN disclosed
CN-118126009-A Coumarin derivative, preparation method and application 成都纽瑞特医疗科技股份有限公司 2024-06-04 — — CN disclosed
US-11701373-B2 Substituted bicyclic compounds BRISTOL-MYERS SQUIBB COMPANY (US) 2023-07-18 — — US disclosed
US-20220331346-A1 SUBSTITUTED BICYCLIC COMPOUNDS BRISTOL MYERS SQUIBB CO (US) 2022-10-20 — — US disclosed
US-11058696-B2 Substituted bicyclic compounds BRISTOL-MYERS SQUIBB COMPANY (US) 2021-07-13 — — US disclosed
EP-3183242-B1 SUBSTITUTED BICYCLIC COMPOUNDS BRISTOL MYERS SQUIBB CO (US) 2021-05-19 — — EP disclosed
WO-1995021162-A1 PROCESS FOR MAKING HIV PROTEASE INHIBITORS MERCK & CO., INC. (US) 1995-08-10 — — WO disclosed
WO-1995002583-A1 PROCESS FOR MAKING HIV PROTEASE INHIBITORS MERCK & CO., INC. (US) 1995-01-26 — — WO disclosed
WO-1994022846-A1 COMPOUNDS ENHANCING ANTITUMOR ACTIVITY OF OTHER CYTOTOXIC AGENTS PFIZER INC. (US) 1994-10-13 — — WO disclosed
US-5204463-A Substituted methoxyphenyl-4,5 dihydro-3(2H)-pridazinones having cardiotonic and beta blocking activities GLAXO INC. (US) 1993-04-20 — — US disclosed
US-5096904-A Congestive heart failure GLAXO INC. (US) 1992-03-17 — — US disclosed
US-5053338-A Hydrolysis of ester to obtain an optically enriched mixture of a phenol enantiomer GLAXO INC. (US) 1991-10-01 — — US disclosed
EP-0412814-A2 Pyridazinones having cardiotonic and beta blocking activity GLAXO WELLCOME INC. (US) 1991-02-13 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220331346-A1 SUBSTITUTED BICYCLIC COMPOUNDS S1PR1, S1PR3, S1PR2 KMT2A 3470/4885MEN1 2180/4885PRMT5 2799/4885
US-11701373-B2 Substituted bicyclic compounds S1PR1, S1PR3, S1PR2 KMT2A 3470/4885MEN1 2180/4885PRMT5 2799/4885
US-11058696-B2 Substituted bicyclic compounds S1PR1, S1PR3, S1PR2 KMT2A 3470/4885MEN1 2180/4885PRMT5 2799/4885
US-20140275576-A1 PROCESS FOR THE PREPARATION OF (2,3-DIHYDRO-BENZO[B][1,4]DIOXIN-2-YL) METHANOL DERIVATIVES CYP1B1, CYP1A1, CYP4B1 KMT2A 1117/4885MEN1 2110/4885PRMT5 4038/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.